Department of Clinical Epidemiology, LUMC, Leiden, the Netherlands.
Circulation. 2010 Nov 2;122(18):1854-61. doi: 10.1161/CIRCULATIONAHA.110.943738. Epub 2010 Oct 18.
Classically, intrinsic coagulation proteins are thought to have a minor role in hemostasis. Recently, these proteins, especially FXII, were implicated as possible key players in the pathogenesis of arterial thrombosis. This study aims to determine the risks of arterial thrombosis conferred by increased activation of intrinsic coagulation proteins in young women and the effect of oral contraceptive use on this association.
The Risk of Arterial Thrombosis In relation to Oral contraceptives (RATIO) study is a population-based case-control study including young women (age 18 to 50 years) with myocardial infarction (n=205) and ischemic stroke (n=175) and 638 healthy controls. Intrinsic coagulation protein activation was determined by measuring activated protein-inhibitor complexes. This complex is with C1 esterase inhibitor (FXIIa-C1-INH, FXIa-C1-INH, Kallikrein-C1-INH) or antitrypsin inhibitor (FXIa-AT-INH). Odds ratios (ORs) and corresponding confidence intervals (95% CIs) were calculated with logistic regression. High levels of protein activation (>90th percentile of controls) showed an increased risk of ischemic stroke: FXIIa-C1-INH (OR, 2.1; 95% CI, 1.3 to 3.5), FXIa-C1-INH (OR, 2.8; 95% CI, 1.6 to 4.7), FXIa-AT-INH (OR, 2.3; 95% CI, 1.4 to 4.0), and Kallikrein-C1 (OR, 4.3; 95% CI, 2.6 to 7.2). If anything, myocardial infarction risk was only increased by Kallikrein-C1-INH (OR, 1.5; 95% CI, 0.9 to 2.5). Oral contraceptive use further increased the risks.
High levels of activated proteins of the intrinsic coagulation system are associated with arterial thrombosis, whereas the strength of these associations differs for myocardial infarction and ischemic stroke. This contradicts similar analyses among men in the Northwick Park Heart Study. Together with the finding that oral contraceptive use further increases the risks, the question of whether the role of intrinsic coagulation proteins in the pathogenesis of arterial thrombosis is sex-specific is raised.
传统上,人们认为内在凝血蛋白在止血中作用较小。最近,这些蛋白,尤其是 FXII,被认为可能是动脉血栓形成发病机制中的关键因素。本研究旨在确定年轻女性内在凝血蛋白激活增加所带来的动脉血栓形成风险,以及口服避孕药对此关联的影响。
动脉血栓形成风险与口服避孕药(RATIO)研究是一项基于人群的病例对照研究,纳入了心肌梗死(n=205)和缺血性脑卒中(n=175)的年轻女性(18 至 50 岁)和 638 名健康对照。通过测量激活蛋白抑制剂复合物来确定内在凝血蛋白的激活情况。该复合物与 C1 酯酶抑制剂(FXIIa-C1-INH、FXIa-C1-INH、激肽释放酶-C1-INH)或抗胰蛋白酶抑制剂(FXIa-AT-INH)结合。采用逻辑回归计算比值比(OR)和相应的置信区间(95% CI)。高蛋白激活水平(高于对照组第 90 百分位数)与缺血性脑卒中风险增加相关:FXIIa-C1-INH(OR,2.1;95% CI,1.3 至 3.5)、FXIa-C1-INH(OR,2.8;95% CI,1.6 至 4.7)、FXIa-AT-INH(OR,2.3;95% CI,1.4 至 4.0)和激肽释放酶-C1(OR,4.3;95% CI,2.6 至 7.2)。如果有的话,心肌梗死风险仅由 Kallikrein-C1-INH 增加(OR,1.5;95% CI,0.9 至 2.5)。口服避孕药的使用进一步增加了这些风险。
内在凝血系统激活蛋白水平升高与动脉血栓形成相关,而心肌梗死和缺血性脑卒中的这些关联强度不同。这与北威克公园心脏研究中对男性的类似分析结果相矛盾。结合口服避孕药使用进一步增加风险的发现,内在凝血蛋白在动脉血栓形成发病机制中的作用是否具有性别特异性的问题被提出。